User profiles for "author:Rohan Garje"

Rohan Garje

Associate Professor FIU, Chief of Genitourinary Medical Oncology, Miami cancer Institute
Verified email at uiowa.edu
Cited by 3196

[HTML][HTML] Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence

RK Vaddepally, P Kharel, R Pandey, R Garje… - Cancers, 2020 - mdpi.com
Cancer is associated with higher morbidity and mortality and is the second leading cause of
death in the US. Further, in some nations, cancer has overtaken heart disease as the …

[HTML][HTML] Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors

P Vikas, N Borcherding, A Chennamadhavuni… - Frontiers in …, 2020 - frontiersin.org
Immunotherapy has revolutionized the treatment of both hematological malignancies and
solid tumors. The use of immunotherapy has improved outcome for patients with cancer …

[HTML][HTML] Comprehensive review of chromophobe renal cell carcinoma

R Garje, D Elhag, HA Yasin, L Acharya, D Vaena… - Critical reviews in …, 2021 - Elsevier
Chromophobe renal cell carcinoma (chRCC) is the third most common type of RCC with
distinct biology compared to other kidney cancer subtypes. The heterogeneity between the …

[HTML][HTML] Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA

P Barata, N Agarwal, R Nussenzveig… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
To report a multi-institutional case series of patients with advanced microsatellite instability
high (MSI-H) prostate adenocarcinoma identified with clinical cell-free DNA (cfDNA) next …

[HTML][HTML] Obesity diminishes response to PD-1-based immunotherapies in renal cancer

SK Boi, RM Orlandella, JT Gibson… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Obesity is a major risk factor for renal cancer, yet our understanding of its effects
on antitumor immunity and immunotherapy outcomes remains incomplete. Deciphering …

Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: ASCO endorsement of College of American Pathologists guideline

P Vikas, H Messersmith, C Compton… - Journal of clinical …, 2023 - ingentaconnect.com
PURPOSE The College of American Pathologists (CAP) has developed a guideline on
testing for mismatch repair (MMR) and microsatellite instability (MSI) for patients considered …

[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy.

P Kuo, J Hesterman, K Rahbar, AT Kendi, XX Wei… - 2022 - ascopubs.org
5002 Background: In the phase 3 VISION study, gallium (68Ga) gozetotide (68Ga-PSMA-11)
PET/CT imaging was used to determine eligibility for lutetium (177Lu) vipivotide tetraxetan …

[HTML][HTML] Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and …

R Vaddepally, R Doddamani, S Sodavarapu… - Biomedicines, 2022 - mdpi.com
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced
malignancies, including non-small cell lung cancer (NSCLC). These agents have improved …

Fibroblast growth factor receptor (FGFR) inhibitors in urothelial cancer

R Garje, J An, M Obeidat, K Kumar, HA Yasin… - The …, 2020 - academic.oup.com
Dysregulated fibroblast growth factor receptor (FGFR) signaling is associated with several
cancers, including urothelial carcinoma. Preclinical studies with FGFR inhibitors have shown …

[HTML][HTML] Breast cancer patients from the Midwest region of the United States have reduced levels of short-chain fatty acid-producing gut bacteria

RL Shrode, JE Knobbe, N Cady, M Yadav, J Hoang… - Scientific reports, 2023 - nature.com
As geographical location can impact the gut microbiome, it is important to study region-
specific microbiome signatures of various diseases. Therefore, we profiled the gut …